Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

US-based molecular diagnostic company Co-Diagnostics has submitted its Logix Smart COVID-19 Test technical file for CE Mark registration.

The firm expects the CE marking later this month as an in vitro diagnostic (IVD) for markets that consider a CE marking as valid approval.

Logix Smart COVID-19 test uses the company’s CoPrimer technology to identify the presence of ribonucleic acid (RNA) of the novel coronavirus in a real-time RT-PCR kit that targets conserved regions in the virus genome.

Co-Diagnostics CEO Dwight Egan said: “We are pleased to announce this milestone, which comes after weeks of hard work by our team at Co-Diagnostics to develop a high-performance diagnostic to help prevent the spread of the new strain of coronavirus.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Our patented CoPrimer molecules have unique properties that lead to a significant reduction in false-positive test results over other polymerase chain reaction (PCR) technologies, but will also allow for enhanced multiplexing, or identifying multiple targets at once, as we iterate the test to include other strains of coronavirus and mutations of COVID-19.”

Co-diagnostics stated that the submitted technical document contains the description of the test to support conformance to the CE marking standards, which will confirm that the test meets the Essential Requirements of the European Community’s In-Vitro Diagnostic Medical Device Directive (IVDD 98 / 79 / EC).

Upon registration process completion later this month, the sale of the product may commence as CE-marked IVD.

Earlier this month, Co-Diagnostics launched a research use only (RUO) CoPrimer test for coronavirus (2019-nCoV).

Coronavirus deaths have climbed to 2,247, including 2,236 recorded in Mainland China, as of the end of 20 February. In Hubei province, the total number of deaths stands at 2,144.

The total number of confirmed cases increased to more than 76,000, with more than 75,400 in mainland China. The total number of recoveries exceeded 18,400.

In mainland China, the number of recoveries increased to 18,264, with 5,206 suspected cases.